Artiva Biotherapeutics (NASDAQ:ARTV) Issues Quarterly Earnings Results

Artiva Biotherapeutics (NASDAQ:ARTV) posted its quarterly earnings results on Friday. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.07), FiscalAI reports.

Artiva Biotherapeutics Price Performance

ARTV traded down $1.63 during midday trading on Friday, reaching $10.89. 5,282,467 shares of the company’s stock traded hands, compared to its average volume of 360,749. The firm has a fifty day moving average of $7.59 and a two-hundred day moving average of $5.35. The stock has a market capitalization of $269.20 million, a price-to-earnings ratio of -3.18 and a beta of 2.86. Artiva Biotherapeutics has a 52 week low of $1.47 and a 52 week high of $14.53.

Trending Headlines about Artiva Biotherapeutics

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: Artiva reported positive initial data for AlloNK across multiple autoimmune diseases, including a 71% ACR50 response in refractory rheumatoid arthritis patients, and said the FDA agreed to a single Phase 3 registrational trial design for AlloNK plus rituximab in refractory RA. Article Title
• Positive Sentiment: Management highlighted that the Phase 3 trial could begin in the second half of 2026, with a meaningful market opportunity in heavily pretreated rheumatoid arthritis patients, supporting the long-term bull case. Article Title
• Neutral Sentiment: Artiva also reported first-quarter 2026 results and outlined recent business progress, reinforcing investor focus on the company’s pipeline and upcoming clinical milestones. Article Title
• Neutral Sentiment: The company’s quarterly loss was slightly worse than expected, but the earnings miss was not the main market-moving catalyst compared with the clinical updates and financing news. Article Title
• Negative Sentiment: Artiva priced a $300 million stock and pre-funded warrant offering, which likely pressured the shares because it increases dilution even as it strengthens the balance sheet. Article Title
• Negative Sentiment: Investor enthusiasm for the strong data appeared to be tempered by concern that the financing may offset some of the upside from the trial progress. Article Title

Analyst Ratings Changes

Several equities research analysts recently weighed in on ARTV shares. HC Wainwright increased their target price on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a report on Friday. Wall Street Zen downgraded Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, April 28th. Needham & Company LLC reissued a “buy” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research note on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $25.33.

Institutional Trading of Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC lifted its position in shares of Artiva Biotherapeutics by 419.3% in the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after purchasing an additional 644,658 shares during the period. BNP Paribas Financial Markets lifted its holdings in Artiva Biotherapeutics by 14,463.5% in the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after buying an additional 117,733 shares during the period. Marshall Wace LLP bought a new stake in Artiva Biotherapeutics during the 4th quarter valued at approximately $341,000. Jane Street Group LLC purchased a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $67,000. Finally, Landscape Capital Management L.L.C. purchased a new position in shares of Artiva Biotherapeutics in the 3rd quarter valued at approximately $112,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.